Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $4.7MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ra Capital Management, L.p. | 10% Owner | Feb 20 '26 | Buy | $7.27 | 74,751 | $543,440 | 1,182,624 | Apr 13 05:20 PM |
| Ra Capital Management, L.p. | 10% Owner | Feb 19 '26 | Buy | $7.21 | 74,268 | $535,472 | 1,107,873 | Apr 13 05:20 PM |
| Ra Capital Management, L.p. | 10% Owner | Feb 18 '26 | Buy | $7.04 | 74,577 | $525,022 | 1,033,605 | Apr 13 05:20 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.